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Abstract  
Minimal residual disease (MRD) is a powerful prognostic factor in acute 
lymphoblastic leukemia (ALL) and is used for patient stratification and treatment 
decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. 
This uncertainty results largely from methodological differences relating to the use of 
real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for 
MRD analysis. We here describe the first results by the EURO-MRD consortium on 
standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph+ALL, designed 
to overcome the lack of standardisation of laboratory procedures and data 
interpretation. Standardised use of EAC primer/probe sets and of centrally prepared 
plasmid standards had the greatest impact on reducing interlaboratory variability. In 
QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log 
difference were 40/67 (60%) and 52/67 (78%) at 10-3 and 36/67 (53%) and 53/67 
(79%) at 10-4 BCR-ABL1/ABL1.  Standardized RNA extraction, cDNA synthesis and 
cycler platforms did not improve results further, whereas stringent application of 
technical criteria for assay quality and uniform criteria for data interpretation and 
reporting were essential. We provide detailed laboratory recommendations for the 
standardized MRD analysis in routine diagnostic settings and in multicenter clinical 
trials for Ph+ALL.  
Introduction 
Minimal residual disease (MRD) during treatment for acute lymphoblastic leukemia 
(ALL) is predictive of outcome and is an accepted measure of response in pediatric 
and adult ALL.(1-11) The value of MRD for therapeutic decisions (6, 12) relies on the 
precision and reproducibility of MRD measurements. For Ph-negative ALL, these are 
typically based on DNA-based quantitative PCR (qPCR) analysis of immunoglobulin 
(Ig) and T-cell receptor (TCR) gene rearrangements. This methodology has been 
optimized and standardised internationally as part of the BIOMED concerted action 
(13, 14) and subsequently the EuroMRD Consortium, formerly European Study 
Group on MRD detection in ALL (ESG-MRD-ALL). (14-18)  
For Ph+ALL, standard MRD monitoring of BCR-ABL1 by qRT-PCR has been 
suggested to provide better and earlier prediction of relapse than the Ig/TCR 
approach.(19) Advantages of reverse transcription real-time quantitative PCR (qRT-
PCR) include high sensitivity, speed and low cost, without need for identification of 
patient-specific MRD markers. Major limitations are the diversity of qRT-PCR 
protocols, instability and variable expression levels of RNA, risk of cross-
contamination and variability in data interpretation and reporting of results. Thus, 
clinical trials using comparable therapeutic regimens for Ph+ALL have reported 
widely varying rates and degrees of molecular response after induction and 
consolidation therapy.(1, 20-26) As precise and reproducible MRD measurements 
are critical to ensure comparability of results between trials and the validity of MRD-
based treatment decisions, standardisation of qRT-PCR procedures, agreement on 
data interpretation and stringent quality control (QC) measures are essential.(16, 18, 
27-30)   
Initial efforts to standardize qRT-PCR analysis were conducted within the Europe 
Against Cancer (EAC) program, which designed and validated EAC primer and 
probe sets for the most frequent leukemia-associated fusion genes.(16, 29) In 
contrast to the chronic myeloid leukemia (CML) community, which initiated 
international and still ongoing standardisation attempts in 2003,(31, 32) no equivalent 
optimisation and standardisation has been conducted for Ph+ALL. The importance of 
high sensitivity and accuracy of quantitating MRD levels in this clinically aggressive 
disease (33) prompted us to comparatively evaluate the impact of methodological 
differences in qRT-PCR analysis of BCR-ABL1, to assess measures to improve the 
inter-laboratory variability and reproducibility of e1a2 BCR-ABL1 detection, and to 
define guidelines for work-flow and reporting of e1a2 BCR-ABL1 transcript levels. 
This study focussed on the e1a2 breakpoint because of its predominance in Ph+ALL, 
as opposed to the e13a2 and e14a2 breakpoints characteristic of CML.(34) We here 
report the consensus recommendations of the EuroMRD Consortium for conducting 
and reporting MRD analyses in patients with Ph+ALL, based on the data generated 
during the first 10 QC rounds. 
 
Organisation and definition of aims 
European multinational cooperative study group trials EsPhALL (35) and EWALL-
PH01 (24) for pediatric and adult Ph+ALL respectively, were the first to focus on 
accuracy and comparability of MRD results generated in the different national 
reference laboratories. Most of these laboratories participated in standardisation and 
quality control studies for immunoglobulin and T cell receptor rearrangement-based 
MRD assessment within the EuroMRD Consortium. Positive experience with these 
studies led to analogous efforts for the RNA-based quantitation of BCR-ABL1. 
Several laboratories of the European Working Group for Adult ALL (EWALL) as well 
as those participating in BCR-ABL1 quantification in CML joined this consortium.  
Successive aims and work programs were designed in biannual group meetings, in 
which results of the studies were discussed. 35 laboratories participated in the first 
10 QC rounds, the results of which are provided in this paper. The coordinating 
centre in Frankfurt was responsible for central preparation and biannual shipment of 
samples, data collection and analysis.  
 
Materials and Methods 
Study Design  
Several successive phases of blinded testing were conducted, described for each 
QC round in supplemental table1. Initially, centrally prepared samples were applied 
to RNA-extraction, cDNA-synthesis and qRT-PCR for BCR-ABL1 and ABL1 with the 
standard reagents and methods used by the participating laboratories by means of 
questionnaires. (Suppl. data)  
A second phase systematically compared the effect of i) RNA-extraction, ii) cDNA 
synthesis, and iii) qRT-PCR by applying routine procedures to centrally produced  
material. cDNA-synthesis and real-time PCR were occasionally repeated on separate 
days to enhance comparability of the individual experimental steps. 
The third phase (QC10) tested the consistency of results and analytical procedures. 
QC7 was a detailed re-analysis of all data generated in QC rounds 1 to 6. 
Quantitative measurement of BCR-ABL1/ABL1 (B/A), and from QC3 onward also 
BCR-ABL1/GUS (B/G), was a common feature of all QC rounds with analyses for 
ABL1 or GUS as control genes (CG), respectively.  
 
Paper tasks 
To standardize interpretation of results, additional “paper tasks” were devised in 
which the laboratories were provided with virtual complex BCR-ABL1/ABL1 and 
BCR-ABL1/GUS measurements and asked for data interpretation and reporting. All 
results were discussed in depth to clarify controversial and discordant results, 
providing a well-founded basis for the development of guidelines.  
 
Centralised sample preparation and quality assessment 
Lyophilised cell dilutions ranging from 1% to 0.001% BCR-ABL1 positive SUP-B15 
cells in BCR-ABL1 negative NALM6 cells, RNA and/or cDNA samples were prepared 
centrally and distributed on dry ice to the participating laboratories. Details of sample 
preparation and distribution are provided as supplemental data. (Suppl. table 1) 
Quality control of the samples prior to shipment was performed centrally by qRT-
PCR using the standardized EAC protocols.(25) BCR-ABL1, ABL1, GUS were 
quantitated in either 3 or 2 independent runs, with one exception (QC8). Samples 
were scored as acceptable when all replicates were within 0.5 log. (Suppl. table 2)   
 
Plasmid standards  
Centrally prepared plasmid standards were provided by Martin Müller (pME-3; 
Medical Faculty Mannheim of the University of Heidelberg, Germany and Nick Cross, 
Helen White (Wessex Regional GeneticsLaboratory, Salisbury, UK). Both vectors 
contain a PCR-insert with e1a2 BCR-ABL1, ABL1 and GUS, and differ only in the 
vector itself and the size of the inserts. After large scale production, the plasmid DNA 
was quantified by spectrophotometry. The plasmid was then linearized and serial 
dilutions were prepared. They were stabilized in a water-based solution containing 20 
ng/µl of msRNA (Roche Diagnostics, Mannheim, Germany). Six dilutions were 
prepared (2 to 2x105 copies). The corresponding standard curve typically generated 
a mean slope of -3.45 and an intercept of 41.57 for pME-3 (calculated from QC3, 4, 
5, 6). A mean CT value of 27 was generated for 10 000 copies of ABL1 with a 
threshold set at 0.1.    
 
Sample analysis by participating laboratories 
Participants were asked to analyse the samples using the workflow given in Suppl. 
table 1. Using questionnaires that were repeatedly sent out throughout the study, 
laboratories also provided information on their in-house methods and standard 
approaches to expressing results and determining positivity and negativity. 
 
Statistical Methods 
All data were analyzed by the coordinating laboratory in Frankfurt. Results were 
presented during Euro-MRD meetings in a non-blinded manner. For Box-plot 
analysis, a 25th–75th percentile box with 10th -90th whiskers was used (median 
marked by line). Regression analysis was performed with the log B/A or B/G of the 
sample sets between individual participating laboratories and reference (log(median 
of B/A or B/G value)). Statistical analysis was performed using the GraphPad Prism 
software package version 6.02 (San Diego, USA). 
 
RESULTS 
Trial participants and routine methodology 
35 laboratories contributed, 8 from the EWALL, 22 from EuroMRD and 5 additional 
laboratories with high sample throughput and/or responsibility for CML validation 
within the EUTOS consortium. The routine methodologies for RNA extraction, cDNA 
synthesis and qRT-PCR are described under supplemental  table 3. 
 
Initial testing phase 
Variability of RNA-Extraction 
In the first QC, RNA extraction was performed from centrally prepared aliquots of cell 
dilutions lysed and homogenized in TRIzol® reagent and shipped on dry ice. The 
amount of RNA extracted from identical aliquots by different laboratories using the 
same extraction method varied substantially, ranging from 0.66 µg to 49.1 µg (Suppl. 
Figure 3A).  
The ABL1 copy number following RNA extraction and cDNA preparation likewise 
showed substantial variability as displayed in the box plots in Supplemental Figure 
3B. Uniform use of TRIzol®–based RNA extraction therefore did not improve inter-
laboratory variability. 
 
Assay sensitivity in relation to control gene  
As a measure of assay sensitivity for the various dilutions of e1a2 BCR-ABL1 
positive cells (total cells per sample: 5x106), the median number of ABL1 copies 
generated during the initial testing phase was 5.4 x 104, (range 0 - 2.41 x 106) (n=22 
laboratories) (Suppl. Figure 3B). Nine laboratories failed to reach the threshold of 104 
ABL1 copies in at least one of seven samples. Overall assay sensitivity across 
laboratories was thus considered suboptimal, despite sufficient cell numbers 
available for extraction.  
Exemplarily, for GUS as CG, the median copy number was 6.4 x 104 (2.13 x 104 - 
3.71 x 106) (QC4, using centrally prepared cDNA). With the exception of one outlier, 
no laboratory measured fewer than 104 GUS copies in any sample (Suppl. Figure 
4B). The median ABL1 amount also revealed sufficient assay sensitivity in all 
laboratories (QC4).  (Suppl. Figure 4A) 
Intra- and inter-laboratory variability was higher when cells instead of cDNA were 
used as starting material, corresponding to the fewer analytical steps prior to the 
qRT-PCR reaction. (Figure 2, Suppl. Figure 1 & 2). 
 
Concordance of BCR-ABL1 transcript levels between laboratories 
As shown in figure 1, the BCR-ABL1/ABL1 ratios varied. Across all QC rounds and 
all samples, the inter-laboratory variability of BCR-ABL1 transcripts levels correlated 
inversely with the number of transcripts analyzed (Figure 1). For example, in QC1, 
the range of B/A ratios in samples with median B/A ratios of 1.99 x 10-1, 4.41 x 10-2; 
2.53 x 10-2 covered a range of 2.26 log, 1.82 log and 1.81 log, respectively. At these 
dilutions, 61/67 (91%), 62/67 (93%) and 56/67 (83%) of analyses measuring BCR-
ABL1/ABL1 ratio were within 1 log of the median and there were no false negatives. 
(Figure 1A) 
For the median B/A of 2.5 x 10-3, 40/67 (60%) analysis were within 0.25 log, 52 of 67 
(78%) analysis were within 0.5 log, 62 of 67 (93%) analyses were within 1 log above 
or below the median. The overall range of B/A ratios was substantially broader (0 to 
0.03) with 2 of 22 laboratories measuring no BCR-ABL1 in this sample. (Figure 1A) 
Deviation from the median at the lowest BCR-ABL1 transcript numbers (sample 6 in 
Figure 1A; median 2.26 x 10-5) was large, ranging from negative to 2.09 log above 
the median. In 21 of 67 analyses (31%) e1a2 BCR-ABL1 was negative in at least one 
replicate. 8/22 (36%) laboratories failed to measure this sample as  positive.  
Data obtained with GUS instead of ABL1 as CG were comparable (Figure 1C & 1D). 
The substantially greater variability of B/A or B/G ratios and a higher proportion of 
negative results at low BCR-ABL1 transcript levels are attributable to low transcript 
numbers often being below the quantitative range of the qRT-PCR assay.  
To determine linearity and sensitivity of the results from each participating laboratory, 
we performed a linear regression analysis in which we compared the log B/A ratios 
obtained by the reference (the median of B/A ratios) and participating laboratories. 
As an example, twenty of 22 (90.9%) local laboratories obtained linear results (R² 
>0.98) when plotted on a log scale (QC1, Suppl. Figure 5A). The non-linear fit of data 
from 2 laboratories suggested an unsatisfactory amplification efficiency of the 
respective PCR technique within the meaningful diagnostic range. Results with GUS 
as CG were similar (QC4, Suppl. Figure 5B).  
 
Impact of methodology on inter-laboratory variability 
Poor reproducibility of BCR-ABL1 quantitation below quantitative range (Figure 1, 
Suppl. Figure 1 & 2) prompted us to assess whether cDNA synthesis performed 
centrally versus locally improved inter-laboratory variability. Centralization RNA 
extraction and cDNA synthesis resulted in only modest improvement of the inter-
laboratory variability of B/A ratios. As shown in Figure 2, the interquartile range was 
slightly smaller when cDNA was produced centrally instead of locally (2.07x10-3 - 
4.78x10-3 vs. 2.63x10-3 - 4.10x10-3; QC6, sample 3). Similarly, the frequency of false-
negative results obtained with centrally (4/26; 15%) or locally (2/26; 8%) synthesised 
cDNA was similar at very low B/A ratios, e.g. 3.41 x 10-5 (Fig. 2, QC6, sample 6). 
Thus, centralisation of cDNA synthesis did not significantly improve inter-laboratory 
variability when transcript levels were below the quantitative range (10 copies). 
SuperScript and M-MLV, the principal enzymes used for cDNA synthesis, were 
comparable in terms of the B/A ratios (Figure 3A) and the ABL1 amount (Suppl. 
Figure 6A), irrespective of the BCR-ABL1 transcript level. Comparison of the cycler 
types revealed no difference with respect to either the B/A ratio (Figure 3B) or ABL1 
amount (Suppl. Figure 6B). 
Inter-laboratory variability decreased with the use of a centrally prepared plasmid 
standards (Fig. 4, Suppl. Fig. 1& 2, 7A & B and Supplemental data).  
 
Sensitivity and specificity 
The frequency of false negative and false-positive results was analysed in all QC 
rounds by evaluating blinded negative and low-positive samples (Table 1). False-
positive results were generated by 12% to 27% of laboratories in 6/10 QC rounds. No 
individual laboratory was disproportionally represented. The frequency of false 
negative results differed by transcript level: at B/A ratios between 1x10-4 and 5x10-4, 
any false negativity occurred in only 2/9 QC rounds, whereas false negative results 
occurred in 6 of 6 QC rounds at B/A ratios below 10-4 (Table 1).   
 
Guidelines for interpretation  
Definition of quantitative range and sensitivity 
The paper tasks revealed that laboratories initially used different criteria for reporting 
qRT-PCR results, particularly with low-level positive samples, e.g. when single 
replicates were positive below 10 BCR-ABL1 copies. We therefore developed 
guidelines for data interpretation analogous to those described for qPCR of Ig/TCR 
rearrangements (17) (Table 2). 
The main difference between these guidelines is a more stringent definition for the 
slope (3.2-3.7) compared with the guidelines published for Ig/TCR quantitation (3.1-
3.9). The BCR-ABL1 assay is a uniformassay and therefore likely to be equally 
efficient between differentpatients, whereas IG/TCR assays are patient-specific and 
therefore highly variable, which accounts for the higher variability in the efficacy of 
the PCR reaction and consequently in a wider range for the slope of the standard 
curve. Based on evaluation of commercial plasmid standard curves (n=65, minor-
BCR-ABL1 standards, QC 1-6), 50% of the slopes were between -3.46 and -3.386 
and 61/65 (94%) were between -3.7 and -3.2, which therefore was chosen 
pragmatically as acceptable range. 154 data sets from in-house plasmid standard 
curves (QC 1-6) were evaluated for defining the acceptable Delta-CT: 2.6 – 4.0 (25th 
-75th percentile 2.882 - 3.633, range 1.4 – 6.4) (Figure 5). 
 
 
 
 Discussion 
 
MRD is an independent prognostic factor for Ph+ALL and may be used as a trigger 
for therapeutic intervention(21-23, 36-42) but validity and comparability of MRD 
results obtained by BCR-ABL1 transcript analysis are uncertain given the lack of 
standardisation.  Our initial comparison of laboratory procedures among participating 
laboratories revealed almost universal use of EAC primer/probe sets (16), which 
were therefore accepted as existing standard. Otherwise, no two laboratories initially 
followed exactly the same protocols, prompting us to evaluate the impact of other 
workflow conditions in successive QC rounds. Data obtained during the consecutive 
QA rounds showed that assay sensitivity was particularly related to an individual 
laboratory´s experience with a qRT-PCR protocol rather than to a specific method. 
Likewise, BCR-ABL1 and control gene copy numbers were not systematically 
affected by the choice of enzymes or type of thermocycler. Successive QC rounds 
showed that adopting the EAC primer/probe sets, common plasmid standards, the 
use of defined technical criteria for quality assurance, and common definitions of 
molecular response and data interpretation, allowed accurate measurement of MRD 
in Ph+ALL across numerous laboratories. There was no apparent benefit in more 
comprehensive standardisation of other components of the laboratory workflow. 
However, use of a secondary reference panel for BCR-ABL1 quantification, as 
recently published for MRD analysis in CML(43) may further improve the accuracy 
and consistency of MRD results across laboratories. 
 
The choice of control gene presently remains controversial. ABL1 is used most 
commonly and yielded results similar to those obtained with GUS, if MRD levels were 
low. However, at higher BCR-ABL1 levels, such as at diagnosis, the use of ABL as 
control gene will underestimate BCR-ABL1 levels relative to control gene levels 
(since the EAC ABL1 PCR will also detect BCR-ABL1 transcripts, control gene levels 
will be over-estimated at high MRD levels). Since BCR-ABL1 MRD levels in ALL are 
frequently expressed relative to levels at diagnosis, the use of GUS as control gene 
seems more appropriate and is therefore strongly recommended.  
 
Throughout the QC rounds, the distinction between detectable and undetectable 
disease was a critical issue at ≤10 BCR-ABL1 copies. It became apparent that this 
challenge was initially compounded by differences in the way individual laboratories 
interpreted data. By conducting paper tasks, it was demonstrated that variable 
approaches to interpretation of the same data sets led to substantial discrepancies in 
the reporting of results, comparable to our experiences for antigen receptor gene 
rearrangements-based MRD analysis.(17) This problem was largely alleviated by 
formulating guidelines for data interpretation and reporting that were adhered to by 
all consortium members, and were reinforced by regular discussions during meetings 
of the consortium. Despite the introduced guidelines, classification of negative 
samples as questionably positive still occurred in all QC rounds; this was however 
not attributable to specific sites, indicating there was no systematic analytical flaw 
affecting individual laboratories. 
 
Although transcript values fell within a half log range in 60% of replicate analyses 
and within 1 log in 78% of replicate analyses (QC1) at a transcript level of 10-3, the 
total range of values spanned a range of up to 3 log. Variability was even more 
pronounced at transcript levels of ≤10-4 and coincided with a clinically relevant rate of 
false positive and false negative results. As expected from comprehensive 
standardisation efforts conducted in the CML field, use of common plasmid 
standards instead of cell lines or e1a2 oligonucleotides in the workflow of all 
laboratories had a profoundly positive impact on interlaboratory variability. Results 
obtained with commercially available, centrally prepared or in-house plasmids were 
comparable. The importance of plasmid calibrators to accurately determine the 
number of BCR-ABL1 and control gene transcripts in CML has led to the 
development of an internationally accepted certified plasmid reference material for 
BCR-ABL1 in CML.(44) A similar approach would be desirable for e1a2 BCR-ABL1 
to ensure international comparability of MRD results for Ph+ALL. Meanwhile, 
laboratories performing MRD testing for multicentre clinical trials of Ph+ALL should 
use identical, centrally prepared or commercial plasmid reference material.  
 
In CML, a test-specific IS conversion factor to enable comparability of BCR-ABL1 
assays was developed and successfully implemented in a large number of 
laboratories, but is expensive and time consuming.(45, 46) Our consensus to not 
implement such a conversion factor for MRD analysis in Ph+ALL reflects reliance on 
a far smaller number of laboratories that also usually function as national or 
cooperative group reference laboratories. Moreover, patients with Ph+ALL are 
treated predominantly within national cooperative group trials rather than in a 
community setting. This different environment with a limited number of laboratories 
facilitates regular participation in QC rounds that are necessary to reinforce 
adherence to agreed guidelines, facilitate data consistency and ensure comparability 
of MRD results, as shown previously for the optimization of MRD analysis based on 
detection of Ig/TCR rearrangements.(14) The EURO-MRD now conducts QC rounds 
for e1a2 BCR-ABL1 analysis twice per year. 
 
As clinical management of Ph+ALL is far more heterogeneous than that of CML, 
depend on diverse treatment protocols and the clinical context, e.g. adult or pediatric 
or pre-versus post-transplant settings, it was not our aim to define specific clinical 
recommendations for MRD testing in Ph+ALL. However, our guidelines listed in 
Table 2 together with the consensus terminology of the second international 
symposium on MRD assessment (15) provide a technical basis for uniform and 
correct interpretation of MRD results.  Nevertheless, a number of clinical 
recommendations can be made based on discussions within our consortium and 
published data. 
 
First, different thresholds and time points have been used by different national 
cooperative study groups to define molecular remission for Ph+ALL. Similarly, timing 
of MRD testing is important but it´s predictive value depends considerably on the 
specific treatment regimen employed, although several underlying principles apply. In 
general, a good early response after induction therapy is more informative of a 
favourable outcome, whereas persisting levels after consolidation are indicative of a 
poor prognosis.(47) During the early treatment period, MRD testing should be 
frequent, e.g. after every other cycle of chemotherapy, with more frequent analyses 
in case of high or rising BCR-ABL1 transcript levels. Testing at a single time-point 
may be informative but serial testing is recommended as it provides important 
information on disease dynamics.(48)  In patients undergoing SCT, MRD should be 
determined within a short time window prior to start of conditioning, as the MRD level 
before SCT may be predictive of outcome.(49, 50) The first post-transplant MRD test 
should be performed approximately 4 weeks after SCT and be followed by more 
frequent analyses than is customary in CML. The EBMT recommends serial 
assessment of BM every 6 weeks and PB every 3 weeks, based on a prospective 
randomized trial investigating two schedules of TKI maintenance after SCT.(37) It 
should be stressed that our analyses was not designed to assign clinical relevance to 
a specific MRD level but to provide a framework for standardised MRD analysis, 
allowing comparison of MRD data from multiple future studies and thereby facilitating 
identification of most informative time points and cut-off levels for Ph+ALL patients. 
 
Second, the material used for MRD analysis clearly impacts on results. As for other 
BCP-ALL, and in contrast to CML, bone marrow is the preferred source for 
quantification of MRD in Ph+ALL, since MRD levels typically are 1 – 3 log higher 
than in peripheral blood, without good correlation between BM and PB.(51)  
In occasional patients it may be difficult to obtain good BM aspirates, particularly 
after SCT with TBI-based conditioning, in which case MRD sensitivity may be higher 
in PB. A large proportion of BM tests carried out prior to extramedullary relapse may 
be negative;(52-54) definite MRD positivity in PB in conjunction with negative results 
in bone marrow may be associated with invasion of extramedullary sites.(55) It is 
therefore advisable to send BM and PB samples in parallel.  
Third, a good quality bone marrow sample, i.e. the first aspirate, should be used for 
MRD analysis. The aspirate should be collected after hematopoietic recovery 
following chemotherapy to ensure sufficient cellularity and assay sensitivity. Prompt 
delivery to the laboratory conducting the MRD analysis is critical, shipment delays 
over 48 h need to be avoided since this may impact transcript levels.(56)  
 
 The upcoming QC and standardisation efforts will be extended to include 
quantification of Major-BCR-ABL1 transcripts, as this breakpoint is present in 
approximately 30% of patients with Ph+ALL. Reagents such as secondary BCR-
ABL1 reference panels developed by the CML field should prove instrumental in 
more rapidly reaching consensus on quantification of this second largest type of 
BCR-ABL1 transcripts. 
 
In conclusion, our guidelines provide a robust framework for precise and reproducible 
qRT-PCR based analyses of e1a2 BCR-ABL1 transcripts and will facilitate valid 
comparison of MRD results between clinical trials for Ph+ALL. Adhering to this 
standard set of recommendations will help answering clinically unresolved questions 
about the prognostic and predictive value of specific BCR-ABL1 thresholds and 
dynamics in distinct therapeutic settings, and help resolve a number of clinical 
management issues that depend on accurate quantification of BCR-ABL1 transcripts.  
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 Figure legends 
 
Figure 1: Inter-laboratory variability of e1a2 BCR-ABL1 transcript levels using ABL1  or GUS 
as CGs using in-house methods. 
BCR-ABL1 quantitation is represented by the ratio of BCR-ABL1 copy number and ABL1 
copy number plotted on the y-axis (log-transformed). On the x-axis, the sample ID represents 
different dilutions of centrally prepared TRIzol®-stabilized cells (panel A), lyophilised cells 
(panel B & D) or cDNA (panel C) that were measured by the participating laboratories in QC 
rounds 1 and 10 for ABL1 and QC rounds 4 and 10 for GUS. In case of repeat analyses, all 
data sets are integrated. The median corresponds to the horizontal line, the box refers to the 
range defined by the 25th and 75th percentiles, the whiskers refer to the range defined by the 
10 -  90 percentiles. Outliers are indicated by dots. Each datapoint represents the mean of 
triplicate analyses of each measurement performed by the participating centers. 
 
 
Figure 2: Inter-laboratory variability of e1a2 BCR-ABL1 quantitation in relation 
to centrally versus locally prepared cDNA  as starting material prior to qRT-PCR  
In QC6, a pool of centrally prepared RNA was separated into aliquots which were either sent 
out to the individual laboratories (n=26) who then performed the cDNA synthesis followed by 
qRT-PCR, or were processed to cDNA, again pooled and then sent out by the central 
laboratory. With these samples, the participating laboratories performed only the quantitative 
PCR. The ratio is defined as the ratio between the copy numbers of BCR-ABL1 and ABL1 
plotted on the y-axis (log-transformed). The median corresponds to the  horizontal line, the 
box refers to the range defined by the 25th and 75th percentiles, the whiskers refer to the 
range defined by the 10-90 percentiles. Outliers are indicated by dots.  Each datapoint 
represents the mean of triplicate analyses of each measurement performed by the 
participating centers. 
 
Figure 3: Inter-laboratory variability of e1a2 BCR-ABL1/ABL1 quantitation in relation to the 
method of cDNA synthesis and cycler platform  
 
Samples were supplied as centrally produced RNA or cDNA, and the participating 
laboratories were asked to perform either cDNA-synthesis and real-time PCR or real-time 
PCR alone (QC6, Sample 1 & 5). On the y-axis the BCR-ABL1/ABL1 ratio of all results 
coming from the individual labs are shown (log-transformed), the LAB ID is given on the x-
axis. Each dot corresponds to the median of three replicates. Panel A is a comparison of 
different cDNA enzymes using MMLV or Superscript. Panel B is a comparison of different 
cycler platforms.Each datapoint represents the mean of triplicate analyses of each 
measurement performed by the participating centers. 
 
 
Figure 4: Inter-laboratory variability of e1a2 BCR-ABL1 transcript quantitation using identical 
plasmid standards. 
 
In QC10, samples with an intermediate (BCR-ABL1/ABL1 ratio 10-3) e1a2 BCR-ABL1 
transcript level were provided as cell pellets. Laboratories were asked to perform RNA 
extraction, followed by two rounds of cDNA synthesis  and qRT-PCR performed on separate 
days. The e1a2 BCR-ABL1/ABL1 ratios for these paired samples are depicted as a quadrat 
for the first and a triangle for the second cDNA synthesis for each individual laboratory, as 
indicated by the lab ID on the x axis. On the right hand side of the two panels, the  horizontal 
line represents the median of all measurements performed by all laboratories, the box refers 
to the range defined by the 25th and 75th percentiles, the whiskers refer to the range defined 
by the 10- 90 percentiles. Outliers are indicated by dots. Each datapoint represents the 
mean of triplicate analyses of each measurement performed by the participating centers. 
 The y axis is scaled to cover 2 logs (log scale).  
 
Figure 5: Ability of laboratories to detect BCR-ABL1 copies within the QR 
An example representing one of 156 datasets showing the ability of participating laboratories 
to detect 10 to 100 BCR-ABL1 copies from the plasmid standard (using in-house plasmids) 
within the quantitative range defined in QC6. On the y-axis, the delta-CT between 10 and 
100 copies is shown. The lab ID is given on the x-axis.  
On the right hand side, the median corresponds to the  horizontal line, the box refers to the 
range defined by the 25th and 75th percentiles, the whiskers refer to the range defined 
by the minimum and maximum. Abbreviations: QR, quantitative range 
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Figure 1: Inter-laboratory variability of e1a2 BCR-ABL1 transcript levels using 
ABL1  or GUS as CGs using in-house methods 
A: e1a2 BCR-ABL1/ABL1 (in-house QC1) B: e1a2 BCR-ABL1/ABL1 (in-house QC10) 
C: BCR-ABL1/GUS (in-house QC4) D: BCR-ABL1/GUS (in-house QC10) 
Figure 1: Inter-laboratory variability of e1a2 BCR-ABL1 transcript levels using 
ABL1  or GUS as CGs using in-house methods 
Figure 2: Inter-laboratory variability of BCR-ABL1 quantitation in relation 
to centrally versus locally prepared cDNA as starting material prior to qRT-PCR 
Figure 3: Inter-laboratory variability of BCR-ABL1/ABL1 quantitation in relation 
to method of cDNA synthesis and cycler platform  
A: local cDNA synthesis and BCR-ABL1/ABL1 ratio, enzymes 
B: local cDNA synthesis and BCR-ABL1/ABL1 ratio by cycler type 
Figure 4: Inter-laboratory variability of e1a2 BCR-ABL1  
quantitation in QC 10 using identical plasmid standards 
A: BCR-ABL1/ABL1 B: BCR-ABL1/GUS 
Figure 5: Ability of laboratories to detect BCR-ABL1 copies within the QR 
 
An example of 154 datasets showing the ability of participating labs to  
detect 10-100 p190 BCR-ABL copies within the quantitative range defined 
in QC6 (with in-house plasmids) 
Table 1: Evaluation of the frequency of false negative and false-positive results 
QC 7
-
-
Batch Batch Batch
A B C A B A B A A A B - A A B A B
pos 22 22 22 20 20 18 18 18 21 pos 26 25 - - - - 23 23
false neg 0 0 0 0 0 0 0 0 0 false neg 0 0 - - - - 0 0
n.a. 0 0 0 0 0 3 3 3 4 n.a. 0 1 - - - - 2 2
pos 22 22 22 20 20 18 18 - - pos 26 25 - - - - - -
false neg 0 0 0 0 0 0 0 - - false neg 0 0 - - - - - -
n.a. 0 0 0 0 0 3 3 - - n.a. 0 1 - - - - - -
pos 22 22 22 20 20 18 18 18 21 pos 26 25 - 28 20 21 23 23
false neg 0 0 0 0 0 0 0 0 0 false neg 0 0 - 0 0 0 0 0
n.a. 0 0 0 0 0 3 3 3 4 n.a. 0 1 - 1 5 4 2 2
pos 21 22 22 20 20 18 18 18 21 pos 26 25 - 28 - - 22 21
false neg 1 0 0 0 0 0 0 0 0 false neg 0 0 - 0 - - 1 2
n.a. 0 0 0 0 0 3 3 3 4 n.a. 0 1 - 1 - - 2 2
pos 22 22 22 20 20 18 17 18 18 pos 26 25 - - 19 21 - -
false neg 0 0 0 0 0 0 0 0 3 false neg 0 0 - - 1 0 - -
n.a. 0 0 0 0 0 3 4 3 4 n.a. 0 1 - - 5 4 - -
pos 22 20 21 16 17 17 18 15 16 pos 22 23 - - - - - -
false neg 0 2 1 4 3 1 0 3 5 false neg 4 2 - - - - - -
n.a. 0 0 0 0 0 3 3 3 4 n.a. 0 1 - - - - - -
false pos 1 1 4 0 0 2 2 0 1 false pos 3 3 - 4 3 0 0 0
neg 21 21 18 20 20 15 13 18 20 neg 23 22 - 23 17 21 23 23
n.a. 0 0 0 0 0 3 3 3 4 n.a. 0 1 - 1 5 4 2 2
QC 10
25
25
sample ID
quality control 
round
no. of labs
no. of returned 
results
sample ID
25
QC 6
26
26
QC 8
29
29
Batch
Median Median Median Median Median Median Median Median Median
-
0,00E+00
Batch Batch Batch Batch Batch
1
2
3
4
5
6
7
1,33E-01
-
1,73E-03
1,39E-03
-
-
0,00E+00
-
-
1,70E-02
-
3,08E-04
-
0,00E+00
-
-
3,41E-02
4,12E-04
-
1,72E-05
0,00E+00
2,34E-01
2,84E-02
3,39E-03
5,71E-04
4,03E-04
3,41E-05
0,00E+00
2,12E-01
-
2,53E-02
3,31E-03
2,31E-04
4,25E-05
0,00E+00
2,54E-01
-
3,31E-02
4,25E-03
3,69E-04
3,09E-05
0,00E+00
2,16E-01
1,10E-01
2,72E-02
7,03E-04
1,31E-04
1,85E-01
3,87E-02
2,21E-02
2,40E-03
2,56E-04
2,85E-05
0,00E+00
20
20
quality control 
round
no. of labs
no. of returned 
results
QC 1
6
7
1
2
3
4
5
2,26E-05
0,00E+00
22*
22
1,93E-01
4,41E-02
2,51E-02
2,57E-03
2,27E-04
QC 2 QC 3
21
21
QC 4
21
21
QC 5 QC 9
26 26
25
 
 
 
*Lab 0 : one analyses more, a total of 67 analyses is available 
Table 2: Guidelines for Assessment of p190BCR-ABL1: Data requirements and 
definitions 
 
Parameter    Criteria 
Standard curve • ≥ 3 standard points for ABL1/GUS, at least in duplicate  
• ≥ 5 standard points for BCR-ABL1, at least in duplicate 
• covering 10 – 105 copies for BCR-ABL1 
• slope: between -3.2 and -3.7 
• correlation coefficient > 0.98 
Quantitative range  Defined by the lowest dilution of standards with: 
• a reproducible Delta-CT of all replicates ≤ 1,5 CT 
• a specific amplification (determined by shape and 
multicomponent graph) 
• mean CT value within 2.6 – 4.0 CT for 1 log difference 
and 0.5 – 1.5 CT for two-fold dilutions 
Sensitivity of the 
assay 
Lowest dilution of standards positive with 
• a specific amplification curve 
• at least one positive replicate (CT with intercept +1) 
independent of the reproducibility and the Delta-CT 
difference 
MRD-Positivity • at least one replicate is positive within Intercept +1 
•  with a specific amplification curve 
• any amplification beyond this point: undetermined, not
clearly negative, questionable positive 
MRD quantitation • if the Delta-CT of the replicates is ≤ 1.5 
• if the mean CT value is less than or equal to the highest CT
value of the quantitative range 
• MRD-positive samples outside the quantitative range:
scored as positive, outside quantitative range.  
Optimal sample 
quality  
 
• ≥10.000 ABL1 copies  
• The minimum ABL1 amount for calculating a ratio should
be evaluated by further patient data. 
 
 
